ClinicalTrials.gg
CompletedNCT03256136Updated Nov 4, 2020Results posted

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

A Phase 2 interventional study of Carboplatin and Nivolumab in Lung Cancer, sponsored by Massachusetts General Hospital. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-04.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 156 studies testing carboplatin in Lung Neoplasms — 9 open to participants now, 18 under way, 3 of them phase 3. Carboplatin · Lung Neoplasms.

Enrollment
119th of 137
9 · median 49
Started
2017
with 4 others
Phase 2
102 of 156
7 open now
Registered
133rd of 156
by date

Among the 156 studies testing carboplatin in Lung Neoplasms, this one is the 119th largest by enrollment of the 137 interventional ones that give a count, is one of 5 that started in 2017, is one of 102 in phase 2, and was the 133rd registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 156 studies testing carboplatin in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies testing carboplatin in Lung Neoplasms, or all of them as a file.
02

Study summary

This research study is studying a drug intervention as a possible treatment for lung cancer.

The drugs involved in this study are:

  • Nivolumab
  • Carboplatin
  • Pemetrexed
  • Ipilimumab
Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease.

The FDA (the U.S. Food and Drug Administration) has approved Nivolumab as a treatment for other types of cancers including lung cancer. However, the combination of Nivolumab with other drugs (such as those being tested in this study) has not been approved by the FDA as a treatment for this type of lung cancer.

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the drug Nivolumab in combination with standard of care chemotherapies, or in combination with Ipilimumab. Nivolumab and Ipilimumab are antibodies (a type of human protein) that are being tested to see if they will allow the body's immune system to work against tumor cells. This study is being done to see if Nivolumab and Ipilimumab, or Nivolumab and chemotherapy drugs (Carboplatin and Pemetrexed), are more effective against cancer when administered together.

These drugs are given as infusions. They are designed to "boost" the immune system's ability to suppress or kill cancer cells that are foreign to the human body.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced (stage IIIB or IV) non-small-cell lung cancer (NSCLC).

    • ALK-rearranged NSCLC: ALK rearrangement as assessed by ALK FISH, IHC, or next-generation sequencing (NGS). For ALK FISH, rearrangements must be detected in >15% of tumor cells.
    • EGFR-mutant NSCLC: EGFR activating gene mutation (e.g., L858R, exon 19 deletion) as well as a T790M mutation per local testing.
  • Presence of at least one as defined by v1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the completion of irradiation.
  • Prior treatment with appropriate tyrosine kinase inhibitors (TKIs) as follows:

    • ALK-positive NSCLC (cohorts B and D): Participants must have progressed on or after 1 or more next-generation ALK-TKI(s).
    • EGFR-mutant NSCLC (cohorts A and C): Participants must have progressed on or after 1 or more third-generation, T790M mutant-selective EGFR-TKI(s).
  • Prior systemic chemotherapy requirements are as follows:

    • Nivolumab plus carboplatin and pemetrexed arms (cohorts A and B): NO prior systemic chemotherapy is allowed. NOTE: Prior or neoadjuvant chemotherapy is allowed if received more than 12 months prior to the study.
    • Nivolumab plus ipilimumab arms (cohorts C and D): Participants must have received a platinum-based combination chemotherapy for their advanced lung cancer and either progressed on/after this chemotherapy or are intolerant. Only ONE is allowed. NOTE: Prior adjuvant or neoadjuvant chemotherapy does not count as an additional line of chemotherapy if received more than 12 months prior to the study.
  • Tumor tissue sample is required following the participant's last line of systemic therapy (TKI or chemotherapy). Tissue sample may be fresh (core needle, excisional, or incisional ), or archival if obtained within 6 months prior to enrollment. There can have been no systemic therapy administered after the sample was obtained. If a tissue sample is available but it has been > 6 months and there has been no intervening therapy, the Principal Investigator may approve the sample after discussion. IHC testing will be performed on the tumor tissue, but positivity on the PD-L1 IHC testing is not required to enroll in the study.
  • Clinically asymptomatic and stable central nervous system (CNS) are allowed (including untreated ) if they have not required increasing doses of or stable doses equivalent to prednisone > 10 mg daily within 2 weeks prior to study entry for CNS symptoms.
  • Prior palliative radiotherapy must have been completed at least 2 weeks prior to study entry.
  • Subjects must have been off any prior systemic anti-cancer treatment (including TKIs) for at least 5 half-lives of that drug.
  • Age ≥ 18 years old.
  • performance status of 0 or 1.
  • ≥ 12 weeks.
  • Screening laboratory values must meet the following criteria:

    • WBC ≥ 2.0 x 109/L
    • Neutrophils ≥ 1.5 x 109/L
    • ≥ 100 x 109/L
    • ≥ 9/dL
    • Serum creatinine ≤ 1.5 x or calculated using Cockcroft-Gault formula ≥ 50 mL/min

      • Female CrCl = (140-age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
      • Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
    • Total ≤ 1.5 x ULN (except in patients with Gilbert's syndrome who may have total bilirubin \< 3.0 mg/dL)
    • and ALT ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present)
  • Females of (defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally for at least 24 consecutive months) must:

    • Have a negative serum or urine pregnancy test obtained within 24 hours prior to starting the drug.
    • Not be breastfeeding.
    • Agree to use, and be able to comply with, highly effective (failure rate less than 1% per year) without interruption while on study treatment plus 5 half-lives of nivolumab (half-life up to 25 days) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post treatment completion. Complete abstinence is acceptable if it is in line with the preferred and usual lifestyle of the patient. Period abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal implants, established and proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods from the options of diaphragm, cervical cap, vaginal sponge, and condom, or progesterone-only oral hormonal contraception where inhibition of ovulation is not the primary mode of action) may be combined to achieve a failure rate of \< 1% per year. Barrier methods must always be supplemented with the use of a spermicide.
  • Male subjects agree to remain abstinent or use a condom plus an additional contraceptive method that result in a failure rate of \<1% per year during sexual contact with a female of childbearing potential while participating in the study, during dose interruptions, and for 31 weeks following the last dose of the study treatment, even if he has undergone a successful vasectomy. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence and withdrawal are not acceptable.
  • Subject has the ability to understand and provide signed .
  • Subject has the willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Subjects previously treated with T cell immune-modulating antibodies, including , anti-PD-1 and/or anti-PD-L1 agents.
  • Subjects with symptomatic , carcinomatous meningitis, spinal cord compression, or intractable back pain due to compression of destructive mass.
  • Subjects with active, known, or suspected disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of randomization (unless used to treat drug-related adverse events). Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Subjects with interstitial lung disease or interstitial pneumonitis that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  • Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days prior to screening. No major surgery, other than diagnostic surgery, is allowed within 4 weeks prior to treatment in the study.
  • Co-administration of anti-cancer therapies other than those administered in the study.
  • Subjects with other active requiring concurrent intervention.
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS). HIV-positive participants are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy, and because there is the potential for pharmacokinetic interactions with combination antiretroviral therapy and study drugs.
  • Any positive test for virus or virus indicating acute or chronic infection.
  • Subjects with ≥ grade 2 peripheral neuropathy at enrollment per the National Cancer Institute (NCI CTCAE).
  • Pregnant or lactating women. Pregnant women are excluded from this study because the study drugs (i.e., nivolumab, ipilimumab, carboplatin, and pemetrexed) have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued.
  • Subjects currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.
  • History of allergy or to any study drugs or their .
  • Any known concomitant medical condition, laboratory abnormality, or psychiatric illness that, in the investigator's opinion, would prevent the subject from participating in the study, pose an unacceptable risk to the patient in this study, or interfere with the interpretation of safety results.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Nivolumab Plus Ipilimumab EGFR

    Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Nivolumab Plus Ipilimumab ALK

    Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive

    Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks

    Drug: Carboplatin · Drug: Nivolumab · Drug: pemetrexed

  • Experimental
    Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive

    Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks

    Drug: Carboplatin · Drug: Nivolumab · Drug: pemetrexed

Interventions

  • Chemotherapy

    Also known as: Paraplatin

  • will allow the body's immune system to work against tumor cells

    Also known as: Opdivo

  • Chemo therapy

    Also known as: Alimta

  • will allow the body's immune system to work against tumor cells

    Also known as: Yervoy

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR), Presented in Numbers of Participants

    Complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease Control Rate (DCR), Presented in Numbers of Participants

    The number of patients that achieved either complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1 * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

    Time frame: Up to approximately 2 years

  2. Progression Free Survival (PFS)

    Time from initiation of the study drugs to progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). Confidence Intervals (CIs) were calculated using the Kaplan Meier (KM) method

    Time frame: From the start of treatment until disease progression or death due to any cause, up to approximately 2 years

  3. Overall Survival (OS)

    Time from initiation of the study drugs to date of death due to any cause. CIs are the KM estimate CIs.

    Time frame: From the start of treatment until death due to any cause, up to approximately 2 years

  4. Duration Of Response

    Time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression).

    Time frame: From the first documented response until disease progression or death, up to approximately 2 years

07

Results

Posted Oct 19, 2020
Limitations and caveats
Early termination leading to small numbers of subjects analyzed.

Participant flow

Participant flow — Overall Study
MilestoneNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Started3141
Completed3141
Not completed0000

Outcome measures

PrimaryObjective Response Rate (ORR), Presented in Numbers of Participants

Complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Objective Response Rate (ORR), Presented in Numbers of Participants
ParticipantsNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Objective Response Rate (ORR), Presented in Numbers of Participants0011
SecondaryDisease Control Rate (DCR), Presented in Numbers of Participants

The number of patients that achieved either complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1 * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Disease Control Rate (DCR), Presented in Numbers of Participants
ParticipantsNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Disease Control Rate (DCR), Presented in Numbers of Participants0031
SecondaryProgression Free Survival (PFS)

Time from initiation of the study drugs to progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). Confidence Intervals (CIs) were calculated using the Kaplan Meier (KM) method

Time frame:
From the start of treatment until disease progression or death due to any cause, up to approximately 2 years
Reported as:
Median · months
Progression Free Survival (PFS)
monthsNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Progression Free Survival (PFS)1.3 (0.6 to 1.4)0.7 (NA to NA)4.65 (1.2 to 8.4)2.8 (NA to NA)
SecondaryOverall Survival (OS)

Time from initiation of the study drugs to date of death due to any cause. CIs are the KM estimate CIs.

Time frame:
From the start of treatment until death due to any cause, up to approximately 2 years
Reported as:
Median · months
Overall Survival (OS)
monthsNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Overall Survival (OS)22.3 (2.6 to 23.7)7.6 (NA to NA)7.75 (2.1 to 16.2)15.9 (NA to NA)
SecondaryDuration Of Response

Time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression).

Time frame:
From the first documented response until disease progression or death, up to approximately 2 years
Reported as:
Median · months
Duration Of Response
monthsNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
Duration Of ResponseNA (NA to NA)NA (NA to NA)0.9 (NA to NA)1.4 (NA to NA)

Adverse events

Collected over From the start of treatment until 30 days after the end of treatment, up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab Plus Ipilimumab EGFR0/3 (0%)0/3 (0%)3/3 (100%)
Nivolumab Plus Ipilimumab ALK1/1 (100%)1/1 (100%)0/1 (0%)
Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive2/4 (50%)3/4 (75%)4/4 (100%)
Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
DyspneaRespiratory, thoracic and mediastinal disorders0/31/10/40/1
Blood bilirubin increaseInvestigations0/30/11/40/1
Skin infectionInfections and infestations0/30/11/40/1
AspirationRespiratory, thoracic and mediastinal disorders0/30/11/40/1
SeizureNervous system disorders0/30/11/40/1
AnemiaBlood and lymphatic system disorders0/30/11/40/1
Neutrophil count decreaseBlood and lymphatic system disorders0/30/11/40/1
VertigoEar and labyrinth disorders0/30/11/40/1
FallInjury, poisoning and procedural complications0/30/11/40/1
Most frequent other events
Showing 10 of 61
Most frequent other events
EventNivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo Naive
ConstipationGastrointestinal disorders1/30/12/41/1
DyspneaRespiratory, thoracic and mediastinal disorders2/30/11/41/1
AnxietyPsychiatric disorders0/30/10/41/1
FatigueGeneral disorders2/30/14/40/1
AnemiaBlood and lymphatic system disorders0/30/13/40/1
AnorexiaMetabolism and nutrition disorders2/30/11/40/1
PainGeneral disorders1/30/12/40/1
Aspartate aminotransferase increasedInvestigations1/30/12/40/1
NauseaGastrointestinal disorders1/30/12/40/1
VomitingGastrointestinal disorders1/30/12/40/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo NaiveTotal
<=18 years00000
Between 18 and 65 years11215
>=65 years20204
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo NaiveTotal
Female21104
Male10315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo NaiveTotal
American Indian or Alaska Native00000
Asian10203
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White21216
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Nivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo NaiveTotal
United States31419
Treatment Regimen Received
Treatment Regimen Received(Participants)Nivolumab Plus Ipilimumab EGFRNivolumab Plus Ipilimumab ALKNivolumab + Carboplatin + Pemetrexed With EGFR Chemo NaiveNivolumab + Carboplatin + Pemetrexed ALK Chemo NaiveTotal
Count of participants31419
08

Study locations

3 sites
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Massachusetts general Hospital
    Boston, Massachusetts 02214, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2019, 20 months.

Results were first posted in Oct 2020, 1 year 2 months after primary completion.

Of 286 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 113. This study's 20 months is below that.

Counting every sponsor, half of 363 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 21, 2017
StartActual
Nov 22, 2017
Primary completionActual
Aug 19, 2019
CompletionActual
Aug 19, 2019
Results first posted
Oct 19, 2020
Last update
Nov 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03256136
Responsible party
Alice Shaw (Director, Center for Thoracic Cancers, Massachusetts General Hospital) — Principal investigator
First posted
Aug 21, 2017
Start date
Nov 22, 2017
Primary completion
Aug 19, 2019
Completion
Aug 19, 2019
Results posted
Oct 19, 2020
Last update
Nov 4, 2020

Study contacts

Alice Shaw, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Nivolumab · Pemetrexed · Ipilimumab

Start the discussion